Beam Therapeutics Inc.

BMV:BEAM * Stock Report

Market Cap: Mex$46.3b

Beam Therapeutics Management

Management criteria checks 3/4

Beam Therapeutics' CEO is John Evans, appointed in Apr 2017, has a tenure of 7.67 years. total yearly compensation is $6.28M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth MX$510.41M. The average tenure of the management team and the board of directors is 4.9 years and 3.9 years respectively.

Key information

John Evans

Chief executive officer

US$6.3m

Total compensation

CEO salary percentage10.9%
CEO tenure7.7yrs
CEO ownership1.1%
Management average tenure4.9yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Evans's remuneration changed compared to Beam Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$144m

Jun 30 2024n/an/a

-US$143m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$685k

-US$133m

Sep 30 2023n/an/a

-US$314m

Jun 30 2023n/an/a

-US$327m

Mar 31 2023n/an/a

-US$316m

Dec 31 2022US$9mUS$650k

-US$289m

Sep 30 2022n/an/a

-US$315m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$238m

Dec 31 2021US$14mUS$590k

-US$371m

Sep 30 2021n/an/a

-US$401m

Jun 30 2021n/an/a

-US$408m

Mar 31 2021n/an/a

-US$366m

Dec 31 2020US$907kUS$529k

-US$196m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$106m

Dec 31 2019US$2mUS$473k

-US$91m

Sep 30 2019n/an/a

-US$86m

Jun 30 2019n/an/a

-US$134m

Mar 31 2019n/an/a

-US$124m

Dec 31 2018US$4mUS$441k

-US$117m

Compensation vs Market: John's total compensation ($USD6.28M) is above average for companies of similar size in the MX market ($USD658.69K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Evans (46 yo)

7.7yrs

Tenure

US$6,280,099

Compensation

Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2020. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...

Leadership Team

NamePositionTenureCompensationOwnership
John Evans
CEO & Director7.7yrsUS$6.28m1.1%
MX$ 510.4m
Giuseppe Ciaramella
President4.9yrsUS$2.79m0.12%
MX$ 57.6m
Christine Bellon
Senior VP5.7yrsUS$2.28m0.054%
MX$ 25.3m
Amy Simon
Chief Medical Officer3.8yrsUS$2.55m0.0017%
MX$ 797.2k
Feng Zhang
Co-Founderno datano datano data
David Liu
Co-Founderno datano datano data
J. Joung
Co-Founderno datano datano data
Sravan Emany
Chief Financial Officerno datano datano data
Manmohan Singh
Chief Technology Officerno datano datano data
Gopi Shanker
Chief Scientific Officer1.8yrsno datano data
Susan O'Connor
Chief Human Resources Officer7.3yrsno datano data
Brian Riley
Chief Manufacturing Officerno datano datano data

4.9yrs

Average Tenure

55yo

Average Age

Experienced Management: BEAM *'s management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Evans
CEO & Directorno dataUS$6.28m1.1%
MX$ 510.4m
John M. Maraganore
Independent Director3.1yrsUS$435.22k0%
MX$ 0
Mark Fishman
Independent Lead Director6.6yrsUS$465.22k0.021%
MX$ 9.9m
Graham Cooper
Independent Director5.2yrsUS$450.22k0%
MX$ 0
Kathleen Walsh
Independent Director3.9yrsUS$447.72k0%
MX$ 0
Chirfi Guindo
Directorno datano datano data
Christi Shaw
Independent Directorless than a yearUS$772.68kno data
Carole Ho
Independent Director6.1yrsUS$442.72k0%
MX$ 0

3.9yrs

Average Tenure

57.5yo

Average Age

Experienced Board: BEAM *'s board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:04
End of Day Share Price 2024/11/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beam Therapeutics Inc. is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Evan SeigermanBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research